Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 447-453

  Blanchet, Pierre J ^a   Papa, Stella M ^a   Metman, Leo Verhagen ^a   Mouradian, M Maral ^a   Chase, Thomas N ^a  

^a Natl Inst Nerv Disord and Stroke   (United States)

Author keywords

Dopamine; Glutamate; NMDA

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; BENSERAZIDE; BUDIPINE; DEXTROMETHORPHAN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; IFENPRODIL; LAMOTRIGINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; QUINIDINE;

ARTICLE; BASAL GANGLION; DENERVATION; DOPAMINERGIC SYSTEM; DYSKINESIA; GLUCOSE UTILIZATION; LOCOMOTION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANTIPARKINSON AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MOVEMENT; PARKINSON DISEASE, SECONDARY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030908103     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00038-3     Document Type: Article

References (80)

1. 1. Albin, R. L.; Young, A. B.; Penney, J. B., The functional anatomy of basal ganglia disorders. Trends in Neuroscience, 12, 366-375 1989.
2. 2. Albin, R. L.; Makowiec, R. L.; Hollingsworth, Z. R.; Dure IV, L. S.; Penney, J. B.; Young, A. B., Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study. Neuroscience, 46, 35-48 1992.
3. 3H]kainate. Brain Research, 658, 209-218 1994.
4. 4. Barbeau, A.; Mars, H.; Gillo-Joffroy, L. Adverse clinical side effects of levodopa therapy. In: McDowell, F. H.; Markham, C. H., eds. Recent advances in Parkinson's disease (Contemporary neurology series, vol. 8). Philadelphia: F.A. Davis Co.; 204-237:1971.
5. 5. Bédard, P. J.; Gomez-Mancilla, B.; Blanchet, P.; Gagnon, C.; Falardeau, P.; Di Paolo, T. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In: Narabayashi, H.; Nagatsu, T.; Yanagisawa, N.; Mizuno, Y., eds. Parkinson's disease: from basic research to treatment (Advances in neurology, vol. 60). New York: Raven Press; 113-118:1993.
6. 6. Bergman, H.; Wichmann, T.; DeLong, M. R., Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 249, 1436-1438 1990.
7. 7. Bergmann, K. J.; Mendoza, M. R.; Yahr, M. D. Parkinson's disease and long-term levodopa therapy. In: Yahr, M. D.; Bergmann, K. J., eds. Parkinson's disease (Advances in neurology, vol. 45). New York: Raven Press; 463-467:1986.
8. 8. Blanchet, P. J.; Calon, F.; Martel, J. C.; Bédard, P. J.; Di Paolo, T.; Walters, R. R.; Piercey, M. F., Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D-2 agonist (U-91356A) in MPTP monkeys. Journal of Pharmacology and Experimental Therapeutics, 272, 854-859 1995.
9. 1 receptor agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Movement Disorders, 11, 91-94 1996.
10. 10. Blanchet, P. J.; Verhagen Metman, L.; Mouradian, M. M.; Chase, T. N. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Movement Disorders, 11, 580-581 1996.
11. 11. Blin, J.; Bonnet, A. M.; Agid, Y., Does levodopa aggravate Parkinson's disease? Neurology, 38, 1410-1416 1988.
12. 12. Boldry, R. C.; Chase, T. N.; Engber, T. M., Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions. Journal of Pharmacology and Experimental Therapeutics, 267, 1454-1459 1993.
13. 13. Boldry, R. C.; Papa, S. M.; Kask, A.; Chase, T. N., MK-801 reverses effects of chronic levodopa and D1 and D2 dopamine agonist-induced rotational behavior. Brain Research, 692, 259-264 1995.
14. 14. Bonuccelli, U.; Del Dotto, P.; Piccini, P.; Behgé, F.; Corsini, G. U.; Muratorio, A., Dextromethorphan and parkinsonism. Lancet, 340, 53 1992.
15. 15. Bravi, D.; Mouradian, M. M.; Roberts, J. W.; Davis, T. L.; Sohn, Y. H.; Chase, T. N., Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Annals of Neurology, 36, 27-31 1994.
16. 16. Brenner, M.; Haass, A.; Jacobi, P.; Schimrigk, K., Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations. Journal of Neurology, 236, 153-156 1989.
17. 17. Brotchie, J. M.; Bevan, M. D.; Mitchell, I. J.; Crossman, A. R., Antiparkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors. European Journal of Pharmacology, 183, 943-944 1990.
18. 18. Brotchie, J. M.; Mitchell, I. J.; Sambrook, M. A.; Crossman, A. R., Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disorders, 6, 133-138 1991.
19. 19. Buller, A. L.; Larson, H. C.; Schneider, B. E.; Beaton, J. A.; Morrisett, R. A.; Monaghan, D. T., The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. Journal of Neuroscience, 14, 5471-5484 1994.
20. 20. Cepeda, C.; Buchwald, N. A.; Levine, M. S., Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor sybtypes activated. Proceedings of the National Academy of Sciences USA, 90, 9576-9580 1993.
21. 21. Church, J.; Jones, M. G.; Davies, S. N.; Lodge, D., Antitussive agents as N-methylaspartate antagonists: further studies. Canadian Journal of Physiology and Pharmacology, 67, 561-567 1989.
22. 22. Crossman, A. R., A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonists-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement Disorders, 5, 100-108 1990.
23. 23. Dall'Olio, R.; Gandolfi, O.; Montanaro, N., Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology, 107, 591-594 1992.
24. 24. Di Chiara, G.; Morelli, M.; Consolo, S., Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends in Neuroscience, 17, 228-233 1994.
25. 25. Engber, T. M.; Susel, Z.; Juncos, J. L.; Chase, T. N., Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. European Journal of Pharmacology, 168, 291-298 1989.
26. 26. Engber, T. M.; Anderson, J. J.; Boldry, R. C.; Papa, S. M.; Kuo, S.; Chase, T. N., Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats. Neuroscience, 59, 389-399 1994.
27. 27. Engber, T. M.; Papa, S. M.; Boldry, R. C.; Chase, T. N., NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuro Report, 5, 2586-2588 1994.
28. 28. Fabbrini, G.; Mouradian, M. M.; Juncos, J. L.; Schlegel, J.; Mohr, E.; Chase, T. N., Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Annals of Neurology, 24, 366-371 1988.
29. 29. Fahn, S.; Isgreen, W. P., Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology, 25, 695-700 1975.
30. 30. Gancher, S. T.; Nutt, J. G.; Woodward, W. R., Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance. Movement Disorders, 10, 37-43 1995.
31. 31. Godwin-Austen, R. B.; Frears, C. C.; Bergmann, S.; Parkes, J. D.; Knill-Jones, R. P., Combined treatment of parkinsonism with L-dopa and amantadine. Lancet, i, 383-385 1970.
32. 32. Gomez-Mancilla, B.; Bédard, P. J., Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clinical Neuropharmacology, 16, 418-427 1993.
33. 33. Grandas, F.; Quinn, N.; Critchley, P.; Rohan, A.; Marsden, C. D.; Stahl, S. M., Antiparkinsonian activity of a single oral dose of PHNO. Movement Disorders, 2, 47-51 1987.
34. 34. Halpain, S.; Girault, J.-A.; Greengard, P., Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature, 343, 369-372 1990.
35. 35. Hardie, R. J.; Lees, A. J.; Stern, G. M., On-off fluctuations in Parkinson's disease. Brain, 107, 487-506 1984.
36. 36. Jellinger, K.; Bliesath, H., Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. Journal of Neurology, 234, 280-282 1987.
37. 37. Kaur, S.; Starr, M. S., Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. European Journal of Pharmacology, 280, 159-166 1995.
38. 38. Kelland, M. D. Sr.; Walters, J. R., Apomorphine-induced changes in striatal and pallidal neuronal activity are modified by NMDA and muscarinic receptor blockade. Life Sciences, 50, PL179-PL184 1992.
39. 39. Kitai, S. T.; Kita, H. Anatomy and physiology of the subthalamic nucleus: a driving force of the basal ganglia. In: Carpenter, M. B.; Jayaraman, A., eds. The basal ganglia II. Structure and function -current concepts (Advances in behavioral biology, vol. 32). New York: Plenum Press; 357-373:1987.
40. 40. Klockgether, T.; Turski, L., NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats. Annals of Neurology, 28, 539-546 1990.
41. 41. Kötter, R., Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Progress in Neurobiology, 44, 163-196 1994.
42. 42. Laurie, D. J.; Seeburg, P. H., Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. European Journal of Pharmacology [Molecular Pharmacology Section], 268, 335-345 1994.
43. 43. Leenders, K. L.; Palmer, A. J.; Quinn, N.; Clark, J. C.; Firnau, G.; Garnett, E. S.; Nahmias, C.; Jones, T.; Marsden, C. D., Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. Journal of Neurology Neurosurgery and Psychiatry, 49, 853-860 1986.
44. 44. Lesser, R. P.; Fahn, S.; Snider, S. R.; Cote, L. J.; Isgreen, W. P.; Barrett, R. E., Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology, 29, 1253-1260 1979.
45. 45. Limousin, P.; Pollak, P.; Benazzouz, A.; Hoffmann, D.; Le Bas, J.-F.; Broussolle, E.; Perret, J. E.; Benabid, A.-L., Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet, 345 (8942), 91-95 1995.
46. 46. Löschmann, P.-A.; Lange, K. W.; Kunow, M.; Rettig, K.-J.; Jähnig, P.; Honoré, T.; Turski, L.; Wachtel, H.; Jenner, P.; Marsden, C. D., Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. Journal of Neural Transmission [Parkinson's Disease Section], 3, 203-213 1991.
47. 47. Maj, J.; Skuza, G.; Rogóz, Z., Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. Journal of Neural Transmission [Parkinson's Disease Section], 6, 53-62 1993.
48. 48. Marsden, C. D., Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry, 57, 672-681 1994.
49. 2 receptor synthesis in rat striatum. Molecular Brain Research, 14, 363-368 1992.
50. 50. Mitchell, I. J.; Clarke, C. E.; Boyce, S.; Robertson, R. G.; Peggs, D.; Sambrook, M. A.; Crossman, A. R., Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 32, 213-226 1989.
51. 3H]Glutamate binds to kainate-, NMDA-and AMPA-sensitive binding sites: an autoradiographic analysis. Brain Research, 340, 378-383 1985.
52. 52. Montastruc, J. L.; Rascol, O.; Senard, J. M.; Rascol, A., A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry, 55, 630-631 1992.
53. 53. Montastruc, J. L.; Fabre, N.; Rascol, O.; Senard, J. M.; Blin, O., N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan. Movement Disorders, 9, 242-243 1994.
54. 2 responses in the 6-hydroxydopamine model of Parkinson's disease. European Journal of Pharmacology, 182, 611-612 1990.
55. 2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. Journal of Pharmacology and Experimental Therapeutics, 260, 402-408 1992.
56. 56. Mouradian, M. M.; Juncos, J. L.; Fabbrini, G.; Chase, T. N., Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Annals of Neurology, 22, 475-479 1987.
57. 57. Mouradian, M. M.; Heuser, I. J. E.; Baronti, F.; Fabbrini, G.; Juncos, J. L.; Chase, T. N., Pathogenesis of dyskinesias in Parkinson's disease. Annals of Neurology. 25, 523-526 1989.
58. 58. Mouradian, M. M.; Heuser, I. J. E.; Baronti, F.; Giuffra, M.; Conant, K.; Davis, T. L.; Chase, T. N., Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry, 54, 401-405 1991.
59. 59. Papa, S. M.; Engber, T. M.; Kask, A. M.; Chase, T. N., Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Research, 662, 69-74 1994.
60. 60. Papa, S. M.; Chase, T. N., Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Annals of Neurology, 39, 574-578 1996.
61. 2 dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors. Neuroscience, 60, 97-114 1994.
62. 62. Quinn, N.; Critchley, P.; Marsden, C. D., Young onset Parkinson's disease. Movement Disorders, 2, 73-91 1987.
63. 63. Rabey, J. M.; Nissipeanu, P.; Korczyn, A. D., Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. Journal of Neural Transmission [Parkinson's Disease Section], 4, 277-282 1992.
64. 64. Riederer, P.; Lange, K. W.; Kornhuber, J.; Danielczyk, W., Glutamatergic-dopaminergic balance in the brain. Arzneim.-Forsch. Drug Research, 42, 265-268 1992.
65. 65. Robertson, R. G.; Farmery, M. A.; Sambrook, M. A.; Crossman, A. R., Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Research, 476, 317-322 1989.
66. 66. Rodriguez, M.; Lera, G.; Vaamonde, J.; Luquin, M. R.; Obeso, J. A., Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry, 57, 562-566 1994.
67. 67. Rupniak, N. M. J.; Boyce, S.; Steventon, M. J.; Iversen, S. D.; Marsden, C. D., Dystonia induced by combined treatment with L-Dopa and MK-801 in parkinsonian monkeys. Annals of Neurology, 32, 103-105 1992.
68. 68. Saenz, R.; Tanner, C. M.; Albers, G.; Kurth, M.; Tetrud, J., A preliminary study of dextromethorphan (DM) as adjunctive therapy in Parkinson's disease (PD). Neurology, 43, A155 1993.
69. 69. Savery, F., Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Disease of the Nervous System, 38, 605-608 1977.
70. 70. Shannon, K. M.; Goetz, C. G.; Carroll, V. S.; Tanner, C. M.; Klawans, H. L., Amantadine and motor fluctuations in chronic Parkinson's disease. Clinical Neuropharmacology, 10, 522-526 1987.
71. 71. Smith, Y.; Parent, A., Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Research, 453, 353-356 1988.
72. 2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. European Journal of Pharmacology, 250, 239-246 1993.
73. 73. Steece-Collier, K.; Pazmino, R.; Greenamyre, J. T., Antiparkinsonian effects of CP-101, 606, an N-methyl-D-aspartate-receptor antagonist, in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys [Abstract]. Movement Disorders, 10, 689 1995.
74. 74. Timberlake, W. H.; Vance, M. A., Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Annals of Neurology, 3, 119-128 1978.
75. 75. Trugman, J. M.; Leadbetter, R.; Zalis, M. E.; Burgdorf, R. O.; Wooten, G. F., Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Movement Disorders, 9, 441-446 1994.
76. 76. Ulas, J.; Weihmuller, F. B.; Brunner, L. C.; Joyce, J. N.; Marshall, J. F.; Cotman, C. W., Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. Journal of Neuroscience, 14, 6317-6324 1994.
77. 77. Verhagen Metman, L.; Blanchet, P. J.; Mouradian, M. M.; Chase, T. N. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations [Abstract]. Annals of Neurology (in press).
78. 78. Wachtel, H.; Kunow, M.; Löschmann, P.-A., NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neuroscience Letters, 142, 179-182 1992.
79. 79. Wüllner, U.; Kupsch, A.; Arnold, G.; Renner, P.; Scheid, C.; Scheid R.; Oertel, W.; Klockgether, T., The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology, 31, 713-715 1992.
80. 80. Zipp, F.; Baas, H.; Fischer, P.-A., Lamotrigine-antiparkinsonian activity by blockade of glutamate release? Journal of Neural Transmission [Parkinson's Disease Section], 5, 67-75 1993.